Novel C-Terminal Hsp90 Inhibitor for Head and Neck Squamous Cell Cancer (HNSCC) with in vivo Efficacy and Improved Toxicity Profiles Compared with Standard Agents

Activity of Anticancer Agents in a Three-Dimensional Cell Culture Model

(2010) Victor Sanjit Nirmalanandhan et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

ITZ-1, a Client-Selective Hsp90 Inhibitor, Efficiently Induces Heat Shock Factor 1 Activation

(2010) Haruhide Kimura et al.   CHEMISTRY & BIOLOGY

Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrestin Vivo

(2010) Bonnie Tillotson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Alternate Strategies of Hsp90 Modulation for the Treatment of Cancer and Other Diseases

(2009) Gary Brandt et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Characterization of Celastrol to Inhibit Hsp90 and Cdc37 Interaction

(2009) Tao Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment

(2009) Shanthi Marur et al.   MAYO CLINIC PROCEEDINGS

KU135, a Novel Novobiocin-Derived C-Terminal Inhibitor of the 90-kDa Heat Shock Protein, Exerts Potent Antiproliferative Effects in Human Leukemic Cells

(2009) S. N. Shelton et al.   MOLECULAR PHARMACOLOGY

HPV & head and neck cancer: a descriptive update

(2009) Peter KC Goon et al.   Head and Neck Optical Diagnostics Society

Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

(2008) D. B. Solit et al.   CLINICAL CANCER RESEARCH

Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket

(2008) Alison Donnelly et al.   CURRENT MEDICINAL CHEMISTRY